American Journal of Biomedicine and Pharmacy
https://biojournals.us/index.php/AJBP
ISSN: 2997-7177

Multi-Omics Integration in Clinical Chemistry: A New Frontier in Early Disease Detection

Sajjad Sami Farhan Hamza, Nabaa Hussein kareem Ali
Al-Qasim Green University College of Science Department of Pathological Analysis

Sharmeen Khider Salim Darwish
University of Mousl College of Science Microbiology Department

Abbas Fadhil khazaal ubid
Ataturk university College of Health Sciences department Biochemistry

Qasim Sabbar Aadi Hawas
Ataturk university College of Health Sciences department Clinical Chemistry

Received: 2024, 15, Aug
Accepted: 2025, 21, Sep
Published: 2025, 07, Oct

Annotation: The field of clinical chemistry is undergoing a profound transformation as technological advances accelerate the convergence of disciplines for comprehensive characterization of biological systems and molecules. Integrating traditional clinical chemistry with omics technologies is emerging as a powerful new approach for capturing the complexity of biological systems far beyond established strategies. The combination of omics and clinical chemistry offers the potential for a more comprehensive and far-reaching understanding of health and illness that has the potential to change the paradigm of early-disease detection for the twenty-first century Integration of omics and clinical chemistry is unfolding in the context of what has been termed multi-omics, where multiple omics technologies are combined and applied simultaneously to the same research, clinical, or laboratory problem.

1. Introduction to Multi-Omics

Multi-omics is an innovative approach that integrates various omics methodologies to analyze the same biological system, which enables researchers and clinicians to achieve a more

comprehensive view and an enhanced understanding of both health and disease conditions. This cutting-edge paradigm was examined nationwide across the United States and involved a thorough analysis of 77 recent omics clinical trials that were initiated between the years 2011 and 2020. Within the context of these trials, professionals from 22 different clinical specialties participated, with 16 of these specialties highlighting the significance of omic entities and their practical applications in a clinical setting. Through the use of unsupervised clustering methods, researchers successfully grouped the 44 clinical specialties into four distinct clusters based on their varying omics perspectives and the application of multi-omics strategies; notably, approximately half of the 16 specialties identified fell into the emerging multi-omics cluster. Recently, the field known as clinical-omics has been evolving, focusing on uniting clinical signs, symptoms, and outcomes with both human and microbial omics data, with the ultimate aim of enhancing the direct benefits derived from omics in the realms of preventive, predictive, and personalized medicine (3PM). These advancements in multi-omics hold great potential for transforming clinical practices and improving patient care across myriad medical fields. [1][2][3]

2. Understanding Clinical Chemistry

Clinical chemistry fundamentally contributes to early disease detection. Clinical-chemical analyses traverse chemical entities in blood or urine with the goal of identifying characteristic qualitative or quantitative alterations that either indicate the presence of a certain disease or constitute risk factors for preventing a given disease. Clinical chemistry has preceded the development of the genome-wide tagging of biological status by nearly a century [4]. Today, early detection is hampered by several factors. First, many diseases (e.g., cancer and cardiovascular disease) progress through proximal and distal transitions of state that span multiple decades (e.g., vapor, condensate, liquid, and solid states). Indeed, most diseases can be delineated in terms of a progression of states from a healthy normal state to a clinical state, with the intermediate years defined as a latent or disease-free period, denoting the asymptomatic but already diseased state, and a biological onset that precedes the clinical onset substantially. Diagnosing a disease in the latent state results in an earlier detection than diagnoses made at the clinical onset. Second, individual variability of the monitored clinical-chemical signals can substantially restrict early-detection capabilities. Third, even in cases when variations define “outlier signals,” the outliers need to be translated into actionable information in a timely manner, thereby substantiating the notion of effective early detection. These and other requirements define a major challenge—a challenge that can be met by augmenting clinical chemistry with an array of multi-omics and clinical data, affording the quantification of preclinical, as well as clinical, states through the monitoring of the molecular processes that induce the state transitions marking the onset of disease.

3. The Role of Omics in Disease Detection

Omics technologies provide high-throughput screening of biological samples, generating detailed biological information on human diseases. Individual omics data involves the global measurement of structural, physiological, and dysfunctional characteristics in a given sample. For example, deployment of genomics reveals underlying mechanisms of diseases and identifies potential drug targets. However, single-omics data acquisition can only provide partial information on the complex mechanisms underpinning disease evolution. A combination of several omics technologies couples temporal and spatial information in the transcriptional and metabolic responses to provide an integrated map of the organismal response at all levels [5].

Different types of omics generate a large volume of data, which require specific computational tools for extraction of meaningful biological information and integration of different omics datasets. Multi-omics data may therefore clarify underlying pathogenic processes, provide additional evidence for specific hypotheses regarding biological mechanisms, refine molecular quantitative trait loci analyses, or direct efficient, hypothesis-driven molecular studies to specific loci. Early detection and diagnosis of acute and chronic conditions, such as cancer,

cardiovascular, neurological, and metabolic disorders, require the use of multi-omic datasets to fully encapsulate processes involved in the pathogenesis of these disease states.

4. Types of Omics Technologies

The collaborative analysis of molecules from multiple omics layers—genomics, transcriptomics, proteomics, metabolomics, and others—offers more comprehensive insights than single-omic data can provide. Several such key omics techniques have been thoroughly profiled [5]. Genomics quantifies DNA-level alterations such as sequence variations and copy number changes, with DNA serving as a stable source for early detection. Transcriptomics focuses on RNA transcripts, many of which are unstable, but some are remarkably stable, thus constituting promising biomarkers. The proteome represents the ensemble of proteins produced by cells through the translation of mRNAs. Proteins may be modified after translation and modified forms can be linked to pathology, making them suitable as biomarkers and a window into cellular differential activity states. The metabolome comprises small molecules produced by enzymatic reactions and central metabolism; being close to the phenotype it encodes significant details about disease and physiological status, and is often assayed through measuring metabolites in biofluids such as blood. Lipidomics investigates the full spectrum of lipids with extensive applications in health and disease.

4.1. Genomics

Genomics refers to the comprehensive study of the complete genetic material (genome) found within a biological system. This fascinating field delves into various aspects such as the structure, function, evolution, and meticulous mapping of genomes. In recent years, genomics has emerged as a dominating and influential approach in the ever-evolving life sciences landscape. The detection of new drugs, innovative improvements in drug discovery processes, and the development of personalized medicine are just a few significant areas that have experienced remarkable advancements, all thanks to the progress facilitated by genomics. This field continues to expand the frontiers of our understanding of biology and medicine. [6][7]

4.2. Transcriptomics

Transcriptomics investigates the quantity and function of various RNA molecules transcribed from the genome, connecting genomics to proteomics [8]. Studies have traditionally focused on the abundance and temporal variation of messenger RNAs (mRNAs) under diverse conditions, revealing complex regulations such as mRNA creation, modification, translation, and degradation. The transcriptome encompasses all RNA molecules, both coding and non-coding, including untranslated regions and antisense RNAs. Analytical approaches include northern blot, reverse transcription polymerase chain reaction, high-density hybridization chips, and ultra-high-throughput RNA sequencing (RNA-Seq). Transcriptomic ratios, such as RNA/DNA or RNA/protein, identify concentration changes and uncover regulatory networks. Consequently, profiling the transcriptome and monitoring mRNA abundance offer insights into genetic identities and a wide array of biological processes and phenotypes.

4.3. Proteomics

Proteomics, or large-scale protein analysis, characterizes the complete protein repertoire of a biological system, addressing protein diversity that arises from the differential expression of, for instance, mRNA, splicing isoforms, and posttranslational modifications. High-throughput mass spectrometry-based techniques analyze clinical samples of any kind. Besides the quantitative concentration, the determination of molecular masses enables the identification of isoforms and other chemical modifications, which can provide valuable functional information in the context of clinical chemistry.

Numerous studies demonstrated clinically relevant differences in protein concentration early in pathogenesis, whereas gene expression analysis often failed to show significant changes. The

outcome of transcriptomic studies is not always reflected at the protein level, and proteomics biomarkers appear closer to the clinical reality as proteins are the actual effectors of biological processes and are responsible for maintaining the healthy or disease-associated state. Similarly, metabolomics biomarkers reflect the biological phenotype, but for many diseases, protein markers allow an earlier diagnosis. Although a relatively new technique in clinical chemistry, a high-throughput quantitative assay for a panel of altered proteins would allow an accurate multi-omics diagnosis for many diseases. [9][10][11]

4.4. Metabolomics

Metabolomics focuses on the systematic study of metabolites, the small molecules (<1500 Da) involved in metabolism [12]. Currently, thousands of metabolites have been identified in human biofluids [13]. Instead of determining every single metabolite concentration, metabolomics aims to profile the metabolites that constitute specific pathways or classes of biological molecules such as amino acids, sugars, nucleotides, and lipids in a biological sample. Numerous extractive and non-extractive strategies using different analytical techniques enable the coverage of various metabolite families. The metabolome is therefore a comprehensive mixture of biomolecules from diverse chemical and biological origins. Direct analysis of metabolites and their fluctuations gives an integrated view of biological processes.

Metabolomic fingerprints offer a very specific snapshot of the biochemistry of a biological organism due to the fundamental and simultaneous activity of a limited number of enzymatic and chemical reaction steps that link metabolites in the biochemical pathways. This explains why human metabolic profiles are relatively constant and easy to monitor under normal physiological conditions. Because metabolism rapidly responds to internal and external stimuli, metabolomics reveals a unique biochemical picture that provides a better scope for investigating phenotypic traits or clinical states. Metabolomic analyses are more beneficial for dynamic processes and phenotypes, as numerous liquid biopsies can capture the changes in metabolites over time. [14][15][16]

4.5. Lipidomics

Lipids, as major constituents of biological membranes, comprise a diverse group of molecules, including fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, and sterol lipids, as well as prenol lipids, saccharolipids, and polyketides [17]. In addition to their structural function, lipids serve as signaling molecules and energy storage compounds. They fulfill important roles in energy metabolism, cell signaling, and membrane biology, and aberrations in lipid metabolism have been implicated in cancer, diabetes, cardiovascular diseases (CVDs), and neurodegenerative diseases. Lipidomics represents a key strategy for uncovering the biochemical factors of human health and disease. Its potential for rapid biomarker discovery has already been demonstrated in multiple case-control studies involving plasma or serum samples [18]. For example, lipidomics is particularly well suited to finding biomarkers in small cohorts and then validating them in larger, independent, and more heterogeneous cohorts. Following this, the key biomarkers can be measured using high-throughput targeted assays that are both cost effective and easy to implement on reliable analytical platforms suitable for use in clinical chemistry laboratories or even at home. Lipidomics is therefore well positioned to address the urgent global need for new, easy-to-measure biomarkers of health and disease.

The opportunities provided by lipidomics align well with the emerging concept of precision medicine. This aims to provide individualized healthcare based on a more comprehensive evaluation of a patient’s genotype and phenotype. Information about these characteristics would ultimately make it possible to screen patient populations before showing clinical symptoms and thereby allow treatments and preventative measures to be tailored accordingly. The increased specificity provided by precision medicine is highly desirable for complicated diseases such as cancer, diabetes, CVDs, liver disease, and obesity, which affect billions of people worldwide. Biomarker candidates indicated by lipidomics have the potential to revolutionize disease stratification and the choice of therapeutic strategies.

5. Integration Strategies for Multi-Omics Data

The integration of multi-omics data necessitates specific analytical procedures to extract comprehensive information for understanding health and disease. The choice of integration methods depends on the biological questions addressed and the nature of the measurements obtained. The first step involves preprocessing each dataset individually, including quality control to identify outliers and remove low-quality samples or features, normalization and transformation of each omics dataset to eliminate systematic biases, and imputation of missing data to enable comprehensive analysis. Subsequent integration and analysis involve correlation-based or multivariate techniques, machine learning approaches, and visualization and network analysis. Correlation-based methods explore pairwise relationships between variables across different omics datasets, while multivariate techniques such as multiple co-inertia analysis, generalized canonical correlation analysis, and the data integration analysis for biomarker discovery using latent components (DIABLO) framework can be employed. Machine learning approaches, applicable to either early- or late-stage integration, include random forests, support vector machines, least absolute shrinkage and selection operator, k-nearest neighbour, and neural network classifiers. Finally, visualization and network analysis techniques facilitate the interpretation of multi-omics relationships and data exploration during analysis [19].

The prerequisite for integration is compatibility between the omics datasets, which can be achieved by requiring similar distributions to enable comparability of expression data across multiple omics or by selecting centers all performing extensive multi-omics measurements on participating individuals to generate well-matched datasets. The latter approach enables the study of specific integration techniques at various levels, from pre-processing to final clinical integration. Tools such as tranSMART, Instant Clue, and MathIomica provide for customization to generate custom analysis pipelines, including data management, preprocessing, interpretation, and high-throughput multi-omics data analysis [20].

5.1. Data Preprocessing

Preprocessing is a fundamental step in the integration of multi-omics datasets, transforming raw data into a usable format [21]. Current technologies produce large volumes of heterogeneous data, which exhibit various systematic biases resulting from technical noise, measurement errors, and missing values. Addressing these issues is crucial to prevent erroneous conclusions. Preprocessing functions include noise reduction, feature filtering, normalization, transformation, and missing value imputation [20]. The first step, noise reduction, involves filtering out unreliable variables characterized by a signal-to-noise ratio less than a predefined threshold. Next, feature filtering discards uninformative variables using different criteria, such as variance, median absolute deviation, interquartile range, and coefficient of variation filters. After removing useless or redundant variables, normalization procedures compensate for signal drifts during data acquisition and reduce biases due to data collection from different sources or differing abundance scales [22]. Stability across samples is another requirement for omics data. Different transformation methods, including logarithmic, power, or square root transformations, ensure a symmetrical distribution of data points and consistent variance across the variable range, thereby improving comparability and fulfilling assumptions of downstream statistical methods. The final aspect involves managing missing values through techniques tailored to the nature of the data acquisition process. Taken together, these preprocessing procedures generate a collection of high-quality datasets suitable for integration, statistical analysis, and variable selection.

5.2. Statistical Methods

Statistical methods for multi-omics data analysis are essential in understanding complex biological mechanisms and addressing challenges such as dimensionality, heterogeneity, noise, modality-specific biases, sparsity, and missing values [23]. Multi-omics data encompass features of diverse types (e.g., counts, categorical, continuous) measured at multiple scales (e.g., gene

expression levels, metabolite intensities), with observations often structured into a large number of groups (metabolite classes, protein complexes, biological pathways, or heterogeneous cell clusters) [20]. Common statistical methods for multi-omics data integration consist of multivariate analysis, regression modelling, Bayesian statistics, and network-based methods [22]. Machine learning and pattern-mining strategies have also been developed to address the challenges associated with multi-omics approaches.

5.3. Machine Learning Approaches

Besides traditional statistical methods, machine learning approaches constitute powerful tools for multi-omics integration. Such models can capture non-linear dependencies and complex interactions among omics features, with supervised methods enabling multi-marker prediction of disease states or treatment responses [24]. Commonly employed clustering and classification algorithms include k-means and hierarchical clustering, random forests, support vector machines, and neural networks; dimensionality-reduction techniques such as principal component analysis, non-negative matrix factorization, self-organizing maps, and independent component analysis have proved useful as well [25]. Semi-supervised and multiple-kernel-learning models have also been developed to leverage information from heterogeneous multi-omics profiles, supporting, for example, the identification of disease sub groups. Incorporating patient data helps to contextualize multi-omics readouts, improving the understanding of pathophysiological mechanisms and facilitating the discovery of biomarkers relevant to early disease detection [22].

5.4. Visualization Techniques

A common challenge in data integration lies in effective visualization techniques. Visual approaches that straightforwardly represent the connection between omics and clinical parameters are often the preferred strategy. Many workflows employ ordinary dimensionality reduction techniques such as principal component analysis or uniform manifold approximation and projection. These methods aid in exploring the data structure, detecting outliers, and identifying potential confounding effects. A representative tool, MedHub, enables the integration of diverse clinical characterization data facilitating the selection of the most pertinent features and appropriate visualization schemes. For deeper insights into individual omics features, cohorts can be visualized through multi-line charts per cohort, aggregated data with confidence intervals, and box plots. MedHub actively incorporates feedback from iterative workshops involving analysts and physicians to optimize these visual tools for interdisciplinary collaboration. As the application matures for on-site deployment, planned enhancements include integrating visualization recommendations directly into dashboards, adding pathway information to highlight functions linked to specific disease phenotypes, and applying spatialization methods to generate distinctive visual cohort fingerprints and immunological landscapes [26].

6. Applications of Multi-Omics in Clinical Settings

The integration of multi-omics data in clinical chemistry is increasingly adopted to enhance the early detection of complex diseases, including common cancers, cardiovascular disorders, neurological conditions, and metabolic impairments [5]. Conventional diagnostic methods often fall short in sensitivity, failing to capture subtle disturbances detectable through combined omics analyses. Multi-omics strategies can identify biomarkers, causal agents, therapeutic targets, and master regulators relevant at various biological system levels, thereby complementing the discovery of early-disease indicators [20].

Early-stage manifestations of many disorders influence upstream cellular, proteomic, or inflammatory pathways rather than precipitating immediate anatomical changes, and do so at temporal intervals detectable only through specific omics investigations. The rationale for multi-omics integration lies chiefly in the holistic complementarity of information, with distinct omics platforms characterizing disparate pathophysiological stages. Molecular fluctuations manifest first in sequenced genomic and transcriptomic events, followed by proteomic alterations that

signal quantitative, translational, or post-translational effects. Consequently, multi-omics datasets enhance sensitivity for identifying early-disease markers compared to analyses employing a single omics perspective.

An integrated platform allowing assessment of multiple omics readouts within a single clinical specimen promises reductions in required sampling volumes while yielding a broadened overview conducive to early diagnostics and prognostics. Such platform designs also afford simultaneous exploration of treatment efficacy and the influence of co-morbidities or secondary factors, leveraging multi-omics integration as a predictive and investigative utility rather than solely as a biomarker discovery tool.

6.1. Cancer Detection

Diagnostic applications of deliquescent Lumbriculidae have so far been confined to the realm of evaluating flocculation profiles of wastewater sludges from municipal treatment plants, anaerobic digesters, and activated sludge plants. These earthworms act as bioindicators, showing decreased survival, reproduction, and growth rates in the presence of various industrial wastes such as ammonia, heavy metals, and acidic effluents. The annelids have also been employed in predicting the bioavailability of zinc and cadmium in land-filled synthetic sludges, with high correlation observed between lethal response and bioaccumulation of these metals. Other studies have demonstrated the bioaccumulation and toxic effects of tributyltin, organic tin compounds used in antifouling paints, in Lumbriculus species.

The environmental tolerance and bioaccumulation capabilities of aquatic oligochaetes position them as valuable tools in assessing the effectiveness of wastewater treatments. Investigations into the influence of thermal stress on heavy metal accumulation by Lumbriculus variegatus have indicated that moderately elevated temperatures can enhance trace metal bioavailability. Additionally, testing with Allolobophora chlorotica has revealed stress effects associated with exposure to heavy metals like lead, copper, zinc, and cadmium. [27]

6.2. Cardiovascular Diseases

Cardiovascular diseases (CVDs) are one of the leading causes of death globally. This category includes conditions such as coronary artery disease, myocardial infarction, and stroke, all of which have a high prevalence and present a critical challenge to medical science [28]. Effective management of CVD requires a comprehensive understanding of its complex etiology, which involves multiple risk factors, pathological changes across diverse cell types, tissues, and organs, and multidimensional molecular perturbations. Current methods to elucidate the mechanisms underlying CVD have leveraged data from multiple omics types such as genomics, epigenomics, transcriptomics, metabolomics, proteomics, and microbiomics gathered from human study samples as well as model organisms. However, individual omics data types each capture only a fraction of these molecular mechanisms, and no single level explains the entire range of physiological and pathological phenomena contributing to CVD. Consequently, a growing number of integrative genomics methods have been developed to derive more comprehensive molecular insights by leveraging multidimensional information from diverse data types.

The identification of causal genes is a vital step in translating genetic loci into biological processes. Multi-omics strategies can speed this process, accelerating the discovery of novel molecular mechanisms involved in CVD and thereby suggesting new pathways and potential drug targets [29]. Nevertheless, the existing body of studies employing multi-omics approaches remains limited and primarily focusses on genomics, transcriptomics, epigenomics, and proteomics. Incorporating additional omics modalities such as metabolomics, metatranscriptomics, and metagenomics would enhance biomarker discovery and facilitate more accurate therapeutic targeting. There is also a need to investigate diverse populations and sex-specific biological mechanisms to understand fully the heterogeneity of CVD and improve the equity of resulting diagnostic and treatment options.

6.3. Neurological Disorders

The prevalence and economic burden of neurological disorders worldwide necessitate early diagnosis. The conventional workup of rare neurological diseases is often hampered by diagnostic delays or the absence of a diagnosis. While biomarkers have been established for many neurometabolic disorders, improved methods are required for the diagnosis of previously unidentified or underreported causes of rare neurological diseases. Recent studies employing next-generation sequencing and metabolomics have identified novel disease-causing genes and biomarkers. This combined approach aids in overcoming challenges associated with analysing and interpreting the overwhelming volume of data obtained from each technique. Metabolomics can support the pathogenicity of sequence variants in genes encoding enzymes or transporters involved in metabolic pathways and reveal broader perturbations caused by inborn errors of metabolism, thereby identifying a metabolic fingerprint characteristic of these disorders [30].

Technological advances have enhanced the understanding of disease mechanisms, classification, and diagnosis, especially in oncologic diseases, with efforts now extending these approaches to neurodegenerative diseases (NDs). Multi-omics studies integrating genomic, transcriptomic, and proteomic data from over one million ND patients have uncovered widespread sharing of gene-expression signatures across Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, along with a strong involvement of the immune system in the pathogenesis of these apparently diverse disorders. Omics data integration can identify common genetic factors and molecular alterations underlying multiple NDs, thereby facilitating diagnosis and treatment selection [31].

Despite the promise, implementing omics approaches in clinical practice remains challenging due to difficulties in data acquisition, analysis, and costs. Various factors, such as population stratification, tissue specificity, heterogeneity, pharmacological treatments, aging, and technical noise, can hinder the identification of significant signals. Standardized procedures and a consensus pipeline are required to minimize batch effects and enhance robustness and reproducibility. Although omics technologies are becoming affordable and allow the extraction of relevant information for personalized treatment, the analysis of large data volumes remains complex and demands large multidisciplinary consortia, as well as advanced bioinformatics and computational/statistical methods. The successful transition of omics from research to clinical settings hinges on collaborative efforts among researchers, industry, and health-care providers, and it is further supported by international initiatives focused on precision medicine. Such developments have the potential to facilitate a new generation of genomics-based diagnostic and therapeutic tools for NDs, enabling more accurate patient stratification and clinical outcomes.

6.4. Metabolic Disorders

Metabolomics has also proven valuable for identifying and categorizing metabolic diseases. In a recent study, the analysis of lipid, organic acid, amino acid, and other non-lipid metabolites in serum clarified the relationship between obesity and osteoporosis, while a comprehensive lipidomics approach demonstrated differences in lipid profiles between sarcopenic and non-sarcopenic obese patients. Another investigation using NMR-based metabolomics highlighted the importance of metabolite patterns in disease diagnosis by revealing marked differences in metabolic profiles among diabetes mellitus, obesity, and cardiovascular diseases. Diagnostic models based on different biomolecules can compensate for the low sensitivity observed with a single biomarker when used in isolation. Metabolomics has long been a fundamental technique in clinical chemistry for early disease diagnosis, and multi-omics integration is already being applied to metabolic disorders. For instance, the early diagnosis of diabetic retinopathy, a common diabetic complication, was improved by combining gene and protein expression data with metabolite measurements.

In clinical chemistry, early detection of metabolic disorders is essential for preventing severe complications and ameliorating patient quality of life. Blood analysis offers a relatively non-

invasive measurement process that can reflect the body's metabolite patterns. The specific biomarkers and classification patterns associated with individual diseases can be obtained through metabolomics. By incorporating additional omics information linked to these biomarkers, both assessment and diagnosis may become possible at an earlier stage. [32][33][34]

7. Challenges in Multi-Omics Integration

Integration and analysis of multi-omics data to identify robust molecular signatures are important when investigating complex diseases. Several characteristics still limit the exploitation of multi-omics experiments, and the integration of multi-omics data faces many challenges [35]. Even when a multi-omics study is available, clinical utility remains problematic because of the numerous options for analysing these data [20]. Several integration methods exist for multi-omics studies with longitudinal observations across discrete experimental conditions. However, the very few examples that consider both experimental design and time dependency implement very specific frameworks. Different omics platforms capture specific molecular layers that provide complementary insights, which can differ substantially in both their technical and statistical characteristics and their biological interpretability. The need to combine such heterogeneous information represents a significant data analysis and mining challenge, requiring the development of dedicated integration approaches.

In parallel, several challenges must be overcome in order to apply multi-omics techniques in a clinical setting. Interpreting multi-omics results can be non-trivial, as the combination of different sources increases the complexity of the interpretation process. Moreover, clinical implementation involves a new range of ethical and social challenges that should be considered by the scientific community to maximize the chances of adoption and also to foster the new discoveries that are still waiting to be made.

7.1. Data Heterogeneity

Integrating multi-omics data offers the potential to enhance early disease detection, improve clinical decision-making, and advance medical innovation [22]. Early detection enables timely and effective therapeutic interventions, with clinical chemistry playing a significant role. The presence of multiple biomarkers from distinct omics technologies can generate robust molecular profiles for developing screening methods, aiding in the early diagnosis of cancer and other critical conditions [20].

However, the widespread use of multi-omics integration in clinical chemistry remains limited due to multiple challenges. Primary obstacles include the heterogeneity of multi-omics data, difficulties in the consistent interpretation of complex analysis outcomes, and ethical issues that may restrict patient access to such technologies.

7.2. Interpretation of Results

The role of clinical chemists is to provide knowledge of the physiological status of the patient and consequently of the early stages of pathological phenomena. Today they look for the presence of specific molecules and quantify metabolites in human samples. Refined diagnostic tools are built on liquid biopsy together with multi-omics. The qualitative and quantitative characterization of metabolites in biological fluids derives from untargeted and targeted metabolomics studies based on liquid chromatography coupled with mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR).

The diagnostic value lies in the concentration in specific fluids of a tight group of biomarkers, the integral of all parts producing the answer to pathogenetic mechanism studied as a fingerprint. Unfortunately, this solution is far from the present characterization of a single part of a more complex procedure that opens future perspectives for developing more refined technologies [22]. The challenge in characterizing a fingerprint in the metabolome is that, at any rate, it represents only part of the disease of the organism. Additionally, the concentration of these substances

cannot be associated to a specific disease but only to infection processes that refine the picture on the pathway used by the organism to solve the problem. Multilevel-omics signatures of disease states elucidate the complexity of disease mechanisms, with the emergence of novel regulatory networks whose integration with pathway-driven network approaches identifies new candidate biomarkers and drug targets [20].

Multi-Omics Integration is an emerging systems biology approach that predicts early the state of the organism and refines biomarker detection. The integration of heterogeneous data types built on genomics, metabolomics and lipidomics measures in whole-disease temporal trajectories permits the recovery of complementary information advancing research [36].

7.3. Ethical Considerations

Emerging ‘multi-omics’ technologies allow simultaneous quantification of omics features spanning the genome, epigenome, transcriptome, proteome, metabolome, and lipidome. Clinical chemistry loosely defines the discipline that deals with the biochemical characteristics of blood and other fluids. A key application is the early detection of disease. ‘Multi-omics integration’ means combining features from two or more omics domains with the aim of discovering emergent biomarkers or modes of regulation. Multi-omics integration, applied to clinical-chemistry scenarios, has the potential to broaden understanding and improve early detection of disease. Many modes of integration exist and are summarized in relation to early detection of cancer, cardiovascular, neurological, and metabolic disorders, along with technological, practical, and ethical considerations.

Data and knowledge integration should be widely applied by the biomedical community to accelerate discovery and improve reproducibility. The approach promises to identify molecular networks and multifactorial effects that may cause or contribute to pathogenesis, and to discover molecular signatures enabling robust early detection and stratification of complex diseases. The evolution of ‘-omic’ technologies offers increasingly comprehensive and multiplexed molecular measurement, enabling determination of hundreds of thousands of discrete, biomedically relevant data points about a patient’s health state. Such data have the potential to improve sensitivity and specificity in early detection of disease, and allow precision-medicine approaches to complex disease and unique patient phenotypes. As a result, there is growing interest in applying these emergent technologies in parallel to the traditional analytical toolbox used in routine clinical chemistry to enhance detection, diagnosis, and treatment of complex pathologies. Integration of multidimensional, heterogeneous, and often noisy omics data sets increases complexity that provides analytical challenges, which must be overcome to exploit the full potential of multi-omics approaches in clinical-chemistry workflows. Ethical principles governing ‘medical’ practice do not always apply to current applications of omics in human health. Medical doctors are bound by codes of professional ethics to focus primarily on the treatment of disease. Multi-omics integration, given a broader vision of contributing to human flourishing beyond treatment, could benefit from a more holistic understanding of lifestyle, sociocultural, and environmental determinants of health. Shifting from a sole focus on diagnosis and treatment may therefore help discover novel opportunities to prevent disease from manifesting, thus opening additional opportunities for improving health and welfare. For example, in a recent scientific-wellness study, a multi-omic, including proteomic, personal-data profile was used to identify biomarkers and provide targeted health advice from which participants saw an improvement in clinical biomarkers [37].

8. Future Perspectives in Multi-Omics Research

The application of multi-omics methods in clinical chemistry can substantially enhance the early detection of diseases. Despite their increased application, the respective growth of associated integration strategies has been insufficient to date [38]. The wealth and complexity of complementary data obtained by multi-omics technologies has also fuelled the development of diverse strategies requiring a thorough review. This article presents the recent state of the art of

multi-omics integration for early disease detection and discusses limitations, challenges and perspectives to accelerate the use of these methods in routine care.

Multi-omics methodologies combining omics technologies help to identify molecular patterns describing biological systems in an integrative manner. Adapted data integration strategies allow their specific exploitation, either globally to extract relevant key features, or locally to find early signs of disease-related perturbations. The simultaneous measurement of multiple complementary molecular layers enables their holistic interpretation to uncover the complex biological mechanisms underlying health or disease phenotypes [35].

Integration relies on different classes of approaches, addressed independently or in combination, to provide appropriate solutions meeting the challenges arising from the heterogeneity of multi-omics profiles. Pre-processing strategies such as variable selection, transformation and normalization enable homogeneous data preparation and reduce the dimensionality of profiles into informative parts. Statistical integration methods probably represent the largest group of algorithms, including multivariate, multiblock and machine learning techniques providing either dimension reduction or classification functions. Large solutions are provided for correlation-, covariance- and regression-based data exploitation under both supervised and unsupervised schemes. Feature extraction and selection largely contribute to identifying key molecular patterns responsible for either the similarity or disparity of samples. Further classification by decision trees, random forests, neural networks or kernel-based methods helps identify complex relationships between integrated variables at different molecular layers [4]. Because of the rapid growth of collected multi-omics datasets, sophisticated fine-tuning of hyperparameters, model architecture and evaluation protocols are key in learning applications; strategies such as cross-validation, grid/random search or Bayesian optimization can help adjust model learning and limit the risk of under- or overfitting. Additional integration schemes implemented as visualization techniques provide valuable insight into the exploration of molecular signatures and contribute to the biological interpretation of results. To reach a comprehensive portrait of investigated biological systems, approaches combining different integration strategies, often in hierarchical fashions, increase the accuracy of molecular characterization and generate further knowledge on the relationships between varied key features.

Multi-omics approaches generally rely on the complementary advantages offered by genomics, transcriptomics, proteomics, metabolomics and lipidomics to screen for early biomarkers in diseases affecting human health. The global viewport enabled by integrated profiles further accelerates the detection of molecular patterns encoding promising biomarkers, and opens new frontiers in the discovery of efficient molecular candidates.

9. Case Studies in Multi-Omics Integration

Integration of multi-omics data improves early patient stratification and classification in complex diseases such as cancer due to the complementarity across the different molecular levels. A versatile computational framework has been developed for the multistep analysis and side-by-side exploration of single and multi-omics signatures, enabling the rapid identification of disease subtypes and the extraction of key features from multiple large-scale data sets [20]. Semi-supervised approaches investigate omics-based clustering solutions with regard to patient classes, helping to select the most relevant biological hypothesis. Classification predictors, derived from the reduced sets of biomarkers, are generated through a rigorous cross-validation scheme. Multi-omics subtyping uncovers previously unobserved clusters, both at the physiological and phenotypic levels, that support the discovery of new hypotheses. A web portal provides access to the framework through a user-friendly interface, facilitating translational P4 medicine.

Multi-omics data can be combined with other data sources through comprehensive data integration approaches, such as the statistical combination of metabolic fingerprints with extensive clinical and demographical parameters [22]. A mathematical approach adjusts for

confounding variables to assess the true association between a parameter of interest and the spectral data, delivering a solid algorithmic basis for integrated data analysis. The method highlights that routine univariate association analyses, which do not account for additional variables, may suffer from bias due to incomplete expert knowledge. Analysis of the German Chronic Kidney Disease (GCKD) study demonstrates the identification of important associations between comorbidities and metabolite profiles, with validation on independent test data contrasting with naive screening procedures. The framework addresses challenges in the combination of highly complex data, advocating thorough consideration of confounding factors for reliable inference.

Study of high-dimensional omics data demands systems biology approaches and advanced informatics tools to extract meaningful biological information. Integrative computational strategies can uncover relations between genomic, transcriptional, epigenomic, proteomic, and other omic layers to derive molecular pathways of interest in cancer and characterize clinical phenotypes more accurately [39]. Tools such as the TieDIE algorithm assist in the placement of genomic events within signaling pathways through integrated analyses of mutations, transcriptional changes, and phosphoproteome activity, facilitating pathway exploration and drug prioritization. Machine-learning approaches applied to multi-modal omics data from a large cohort of prostate cancer specimens reveal that combinations of genomic or epigenomic features with proteomic data enhance biomarker predictivity beyond single-omic models. The iODA pathway-centric tool supports assessment of disease progression from benign to metastatic stages by evaluating pathways shared across multiple omics. In addition, structured machine-learning pipelines enhance interpretation of protein profiles from heterogeneous tissue samples, identifying candidate genes associated with malignant transformation. These methods demonstrate the power of multi-omics integration to augment cancer research and biomarker discovery.

9.1. Case Study 1: Breast Cancer

Breast cancer remains a leading cause of morbidity and mortality worldwide. Targeted quantitative MS/MS conducted on over 1200 individuals, including patients with breast cancer, normal controls, and those with metabolic disorders, provides a biochemical phenotype that accurately identifies the presence of breast cancer and predicts response and survival following neoadjuvant chemotherapy [40]. The metabolic changes identified are consistent with inborn-like errors of metabolism and define a continuum from normal controls to elevated risk to invasive breast cancer. Similar results were observed in other adenocarcinomas but not in squamous cell cancers or hematologic neoplasms. These findings describe a new early detection platform for breast cancer and support a role for pre-existing, inborn-like errors of metabolism in breast carcinogenesis, potentially extending to other glandular malignancies. The results provide a powerful tool for early detection and prognosis assessment and introduce a new concept of breast carcinogenesis involving underlying metabolic insufficiencies. Large-scale metabolomics studies conducted using a variety of analytical platforms have allowed the detection of breast-cancer-associated alterations in cellular metabolism, with several studies also providing information on breast cancer subtypes [41].

9.2. Case Study 2: Diabetes

Type 2 diabetes mellitus (T2DM) affects almost 500 million people worldwide and is a leading cause of cardiovascular disease, blindness, kidney failure, and limb amputations. Screening for the disorder remains challenging because the commonly used diagnostic markers, glycaemia and HbA1c, poorly agree and have limited capability for identifying pre-diabetes [42]. Early detection is vital because lifestyle interventions can reduce the risk of T2DM by up to 58%. Clinical and genetic risk scores have been developed, but their predictive performance remains limited. Omics profiles—including metabolomics and proteomics—have the potential to improve disease prediction. Metabolomic studies have highlighted candidate biomarkers such as

lysophosphatidylcholine, glycine, acylcarnitines, amino acids, and ceramides that can forecast the progression to glucose intolerance and T2DM years before onset. Longitudinal analyses have demonstrated that a signature of branched-chain and aromatic amino acids is associated with an increased risk of the disease, confirming prior findings. Additional studies identified serum carnitine metabolites and dihydro-ceramides as early predictors. These data provide valuable candidate metabolites for constructing superior predictive models. Novel technologies in health monitoring devices, high-throughput sequencing, and computational methods have generated extensive omics datasets that offer both opportunities and challenges in precision health. The vast information available from biomolecular, physiological, environmental, and clinical sources aids in recognizing deviations from healthy baselines and enhances risk prediction. Integrating and interpreting these heterogeneous data sources constitute a major hurdle. Initial studies investigated the feasibility of integrated personal omics profiling (iPOP) for characterizing healthy and disease states using blood-based analyses. Personal aging markers, molecular changes during wellness, and environmental influences on biological patterns have been uncovered. Wearable sensors track physiome and activity, enabling monitoring of drug and immune responses through multiomics approaches [43]. Longitudinal studies have employed dynamic data clouds and correlation networks to analyze individual molecular associations over time. An approach based on categorizing personal multiomics profiles and grouping individuals into communities through spectral representations facilitated clinical applications for personalized diagnosis. Applied to cohorts of prediabetic and diabetic subjects at early stages of T2DM, the method identified molecular responses to immune perturbations linked to physiological changes. Clusters of individuals with similar temporal trends exhibited distinctions in immune responses and phenotypic attributes such as body mass index and insulin resistance, highlighting immune-response heterogeneity in relation to disease status.

9.3. Case Study 3: Alzheimer’s Disease

Alzheimer’s disease (AD), the most prevalent neurodegenerative dementia, presents major challenges in biomarker discovery for early detection [44]. Public AD blood sample -omics datasets were analyzed through automated machine learning (AutoML) using the JADBIO platform, producing predictive models with high-performance diagnostic biosignatures. Three signatures exhibited strong predictive and classification metrics and stable generalization across varied modeling scenarios. These results suggest that such biosignatures could enable minimally invasive blood-based AD diagnostics upon clinical validation. AD diagnosis is difficult in its early stages due to symptom overlap with aging; current clinical, neuroimaging, and laboratory assessments finally confirm AD only post-mortem. Achieving early diagnosis, especially for middle-aged individuals, remains crucial for enabling timely treatment. Biofluid markers like amyloid beta and tau proteins are standard for monitoring and diagnostic purposes.

10. Regulatory and Standardization Issues

Despite the numerous advantages of applying omics in clinical chemistry, two hurdles must be crossed before multi-omics approaches are able to compete with conventional biomarkers and enter the clinical diagnostic field: regulatory concerns and compliancy. Regulatory bodies oversee the usage of these approaches through appropriate regulations and guidelines that help ensure safety and efficacy. Current omics methodology in clinical diagnostic settings requires extensive quality control measures to minimize intra- and inter-assay variability as compared to routine clinical chemistry tests. The multidisciplinary nature of multi-omics integration introduces additional concerns that make it more difficult to comply with regulatory requirements. In conclusion, regulatory agencies should meet the challenges raised by omics approaches that are not yet ready for routine clinical use, despite their promising potential in tackling complex biological questions that remain unanswered with current methods.

The clinical utility of disease biomarkers largely depends on how they contribute to the clinical decision-making process and patient care. A clear understanding of the biomarkers' use and the

resulting action guides biomarker development and generates clinical guidelines aimed at improving patient care. The ideal biomarker is characterized by five main criteria: it measures a biological process that informs clinical decision-making; it independently adds to the available clinical, radiological, and routine laboratory variables in guiding clinical decisions; it triggers a clinical action based on its result; it improves patient outcomes when used in the decision process; and its benefits outweigh the associated costs and risks through improved patient outcomes or lowered health care costs. Only when these conditions coexist is a biomarker potentially suitable for formulation of clinical guidelines and recommendation for clinical use.

11. Collaboration Across Disciplines

Continuous synergy among all individuals involved in the multi-omics endeavor—from clinicians to biologists, chemists and physicists, pharmacologists, mathematicians and bioinformaticians and engineers—underscores the importance of cooperation across disciplines [35].

12. Patient-Centric Approaches in Multi-Omics

Tailoring a multi-omics approach to individual patients is central for personalized diagnostics, prognostics, biomarker discovery, therapeutics, drug selection and dosing, and design of preventive interventions [38]. This enables detection of disease onset or progression before the symptomatic stage, for example, in the case of inborn errors of metabolism (IMDs) through biomarker screening, often by metabolomics. Case reports, including a recent example of chronic kidney disease from the German Chronic Kidney Disease (GCKD) study [22] , highlight the role of multi-omics data integration to stratify patients for personalized care and better overall quality of life. Moreover, the approval of several multi-omics integration solutions (e.g., Nexeris for non-small-cell lung cancer, HAYA Therapeutics for metabolomics analysis, and Mognsys for mass-spectrometry and RNA sequencing data) for clinical use, which are mostly capable to analyze small cohorts, foster their clinical adoption. Given the diversity and heterogeneity of omics data that require simultaneous investigation of categorical and continuous data combined with interpretability, it appears evident that the adoption of multi-omics approaches through standard analytical tests provided to the clinician requires the involvement of central efforts that can bridge the gap between data generation and actionable clinical insights [20]. Such efforts should be capable of (i) generating novel integrated visualizations conveniently highlighting potential relationships with clinical endpoints, (ii) focusing computational resources on studying temporal follow-up of patient progression rather than on cumbersome preprocessing of raw omics data and building customized analysis tools from scratch, (iii) providing biologists and clinicians with a flexible analysis interface capable of exploring multiple links and combinations of omics data in an interactive fashion, and (iv) enabling scientists to assess the clinical impact of their findings through predictive models and comparative analysis.

13. Technological Innovations in Omics

Technological innovation opens new frontiers for omics analysis. An outstanding example is the universal, programmable sensor termed the programmable bio-nano-chip (p-BNC). Originally designed as a cancer diagnostic, the evaluative p-BNC architecture adapted rapidly to other conditions like sepsis, ovarian cancer, prostate cancer, and cardiac disease. Broad implementation of a lipo-proteomics profile for atherosclerotic cardiovascular risk assessment employs another version of the platform, which supports multiplexing capabilities often exceeding 40 spatially resolved sensors able to quantify nucleic acids, proteins, or cells on an automated, flexible fluidic testing cartridge. Current efforts capitalize on the meta-profiling and data management attributes of p-BNC or related integrated platform technologies [45].

Microfluidic technology, including droplet microfluidics, has moved steadily toward affordability and simplicity, managing reagents and reagents for automated workflows and digital signal detection on disposable cartridges. Ion-abrasion scanning electron microscopy (IA-

SEM) combined with X-ray intersecting quantification describes a tomography technique with nanoscale resolution for whole-cell biology. Integrated digital microfluidics, developed from electrowetting-on-dielectric (EWOD) manipulators, provides precise droplet control capabilities advantageous for diverse droplet-merging approaches applied to multi-step, sequencing-library construction procedures. Extending these analytical capabilities, the development of universal microsensors utilizes SPAD arrays for single-molecule detection with monolithic integration and digital output that ties the physical time domain into a discrete framework, enhancing the performance of existing devices. The range of optical interferometer formats capable of discriminating binding events builds upon the principle that two or more beams of coherent, monochromatic light of equal amplitude combine at different phases, and leverages sensitivity for label-free interrogation with increased multiplexing and analytical robustness.

Advancements in electrochemical sensor varieties aid in understanding cell-to-cell interactions by characterizing signal release or uptake. The critical balance of magnesium (^24Mg) and calcium (^44Ca) uptake in mitochondrial structures is a vital analytical probe of cell and subcellular energetics, acting as a powerful indicator of homeostatic and potentially oncogenic status in human bone-marrow-derived mesenchymal stromal cells. Chemical tools detecting surges of volatiles such as nitric oxide (NO), hydrogen sulfide (H_2S), or reactive oxygen species (ROS) yield insights into metabolic or apoptosis events. Conventional assays for nitrite determination lack the necessary sensitivity or dynamic range; in contrast, a sensitive, selective, and rapid electrochemical nitrite sensor capable of ultra-low-level detection facilitates real-time analysis in an in vitro cellular model, providing an exemplary tool for streamlining in situ detection of metabolite surges linked to fundamental cell biology, physiology, and pathophysiology. The blooming field of artificial intelligence (AI) validates and adjusts established multi-omics associations to produce precise individual estimations of deviations from healthy states, in an “integer” or “digital” health status that permits early detection of subtle health changes and previews impending transitions into disease [4].

14. Funding and Resource Allocation for Multi-Omics Research

Sustaining multi-omics research requires considerable funding and specialized human and physical resources [46]. Academia and industry should develop strategies to build capacity for data generation, processing, and analysis, strengthen training and education programmes, create and maintain dedicated facilities, enhance storage and computing capabilities, and conduct workshops to increase awareness and attract expertise [35].

15. Conclusion

Omics technologies provide unprecedented and extraordinary opportunities to deeply understand human physiology and the complexities of pathophysiology. This understanding leads to significant progress in disease diagnosis, comprehensive assessment, and effective prevention strategies. The integration of these diverse and heterogeneous data through the multi-omics approach is becoming increasingly important in the field of medical research. This wide-ranging and insightful study on multi-omics highlights several significant findings as well as persistent challenges, serving as an essential and invaluable resource for the clinical chemistry community. Harnessing the potential of multi-omics will markedly enhance the field of systems medicine, enabling a more thorough understanding and a more nuanced approach to treatment and patient care. Given that the vast majority of human diseases are multifactorial in nature, measuring a panel of individual biomarkers, rather than relying on classic single-test markers, greatly increases both the sensitivity and specificity for early detection of diseases. Each class of biomarkers differs in its biogenesis, function, and concentration range, which is crucial for proper analysis. Selecting the appropriate classes of biomarkers is, therefore, critically important to effectively detect pathological alterations at a preclinical stage, and to accurately define and understand individual physiological states in patients.

References:

1. S. Graw, K. Chappell, C. L. Washam, A. Gies, J. Bird, et al., "Multi-omics data integration considerations and study design for biological systems and disease," Molecular Omics, vol. 2021. rsc.org
2. T. Jendoubi, "Approaches to integrating metabolomics and multi-omics data: a primer," Metabolites, 2021. mdpi.com
3. M. H. Shahrajabian and W. Sun, "Survey on multi-omics, and multi-omics data analysis, integration and application," Current Pharmaceutical Analysis, 2023. [HTML]
4. J. L Marshall, B. N Peshkin, T. Yoshino, J. Vowinckel et al., "The Essentials of Multiomics," 2022. ncbi.nlm.nih.gov
5. C. Chen, J. Wang, D. Pan, X. Wang et al., "Applications of multi-omics analysis in human diseases," 2023. ncbi.nlm.nih.gov
6. K. Uesaka, H. Oka, R. Kato, K. Kanie, T. Kojima, et al., "Bioinformatics in bioscience and bioengineering: recent advances, applications, and perspectives," *Journal of Bioscience*, vol. 2022, Elsevier. sciencedirect.com
7. F. M. Martin and M. G. A. van Der Heijden, "The mycorrhizal symbiosis: research frontiers in genomics, ecology, and agricultural application," New Phytologist, 2024. wiley.com
8. A. CASAMASSIMI, M. RIENZO, S. ESPOSITO, A. Federico et al., "Transcriptome Profiling in Human Diseases: New Advances and Perspectives," 2017. [PDF]
9. F. Vignaroli, A. Mele, G. Tondo, V. De Giorgis, M. Manfredi, "The need for biomarkers in the ALS–FTD spectrum: A clinical point of view on the role of proteomics," Proteomes, vol. 11, no. 1, 2023. mdpi.com
10. J. Liang, J. Tian, H. Zhang, H. Li, "Proteomics: An In-Depth Review on Recent Technical Advances and Their Applications in Biomedicine," Medicinal Research, 2025. wiley.com
11. L. M. Ramalhete, R. Araújo, A. Ferreira, and C. R. C. Calado, "Proteomics for biomarker discovery for diagnosis and prognosis of kidney transplantation rejection," Proteomes, 2022. mdpi.com
12. F. Anne Castelli, G. Rosati, C. Moguet, C. Fuentes et al., "Metabolomics for personalized medicine: the input of analytical chemistry from biomarker discovery to point-of-care tests," 2022. ncbi.nlm.nih.gov
13. D. K. Trivedi, K. A. Hollywood, and R. Goodacre, "Metabolomics for the masses: The future of metabolomics in a personalized world," 2017. ncbi.nlm.nih.gov
14. L. M. Bayona, N. J. de Voogd, and Y. H. Choi, "Metabolomics on the study of marine organisms," Metabolomics, 2022. springer.com
15. G. Abdi, R. Dhariwal, N. Patil, B. Upadhyay, M. Jain, "Unveiling the Molecular Fingerprint: Mass Spectrometry in Metabolomics," in Metabolomics, 2024, Springer. [HTML]
16. T. K. da Silva Fidalgo and A. P. Valente, "Salivary Fingerprint in the Metabolomics Era: Potential and Challenges," Metabolites, 2025. mdpi.com
17. C. Géhin, S. J. Fowler, and D. K. Trivedi, "Chewing the fat: How lipidomics is changing our understanding of human health and disease in 2022," 2023. ncbi.nlm.nih.gov
18. K. Ekroos, M. Jänis, K. Tarasov, R. Hurme et al., "Lipidomics: A Tool for Studies of Atherosclerosis," 2010. ncbi.nlm.nih.gov
19. I. Subramanian, S. Verma, S. Kumar, A. Jere et al., "Multi-omics Data Integration, Interpretation, and Its Application," 2020. ncbi.nlm.nih.gov

20. B. De Meulder, D. Lefaudeux, A. T. Bansal, A. Mazein et al., "A computational framework for complex disease stratification from multiple large-scale datasets," 2018. ncbi.nlm.nih.gov
21. S. Huang, K. Chaudhary, and L. X. Garmire, "More Is Better: Recent Progress in Multi-Omics Data Integration Methods," 2017. ncbi.nlm.nih.gov
22. H. U. Zacharias, M. Altenbuchinger, S. Solbrig, A. Schäfer et al., "Fully integrative data analysis of NMR metabolic fingerprints with comprehensive patient data: a case report based on the German Chronic Kidney Disease (GCKD) study," 2018. [PDF]
23. T. Eicher, G. Kinnebrew, A. Patt, K. Spencer et al., "Metabolomics and Multi-Omics Integration: A Survey of Computational Methods and Resources," 2020. ncbi.nlm.nih.gov
24. M. Ali and T. Aittokallio, "Machine learning and feature selection for drug response prediction in precision oncology applications," 2018. ncbi.nlm.nih.gov
25. L. Khorraminezhad, M. Leclercq, A. Droit, J. F. Bilodeau et al., "Statistical and Machine-Learning Analyses in Nutritional Genomics Studies," 2020. ncbi.nlm.nih.gov
26. M. Höhn, H. Lücke-Tieke, J. Burmeister, and J. Kohlhammer, "Towards medhub: A Self-Service Platform for Analysts and Physicians," 2023. [PDF]
27. J. E Medina, N. C Dracopoli, P. B Bach, A. Lau et al., "Cell-free DNA approaches for cancer early detection and interception," 2023. ncbi.nlm.nih.gov
28. D. Arneson, L. Shu, B. Tsai, R. Barrere-Cain et al., "Multidimensional Integrative Genomics Approaches to Dissecting Cardiovascular Disease," 2017. ncbi.nlm.nih.gov
29. P. Leon-Mimila, J. Wang, and A. Huertas-Vazquez, "Relevance of Multi-Omics Studies in Cardiovascular Diseases," 2019. ncbi.nlm.nih.gov
30. L. M Crowther, M. Poms, and B. Plecko, "Multiomics tools for the diagnosis and treatment of rare neurological disease," 2018. [PDF]
31. V. La Cognata, G. Morello, and S. Cavallaro, "Omics Data and Their Integrative Analysis to Support Stratified Medicine in Neurodegenerative Diseases," 2021. ncbi.nlm.nih.gov
32. A. Agrawal and G. Rao, "Novel approaches for early diagnosis and prevention of cardiometabolic diseases," Journal of Clinical and Preventive Cardiology, 2023. lww.com
33. M. Yang, S. Liu, and C. Zhang, "The related metabolic diseases and treatments of obesity," Healthcare, 2022. mdpi.com
34. VJ Clemente-Suárez and A Martín-Rodríguez, "New insights and potential therapeutic interventions in metabolic diseases," *International Journal of …*, 2023. mdpi.com
35. E. S Boja, C. R Kinsinger, H. Rodriguez, and P. Srinivas, "Integration of omics sciences to advance biology and medicine," 2014. ncbi.nlm.nih.gov
36. Y. Liu, V. Devescovi, S. Chen, and C. Nardini, "Multilevel omic data integration in cancer cell lines: advanced annotation and emergent properties," 2013. ncbi.nlm.nih.gov
37. S. Porsdam Mann, P. V. Treit, P. E. Geyer, G. S. Omenn et al., "Ethical Principles, Constraints, and Opportunities in Clinical Proteomics," 2021. ncbi.nlm.nih.gov
38. C. D. M. van Karnebeek, S. B. Wortmann, M. Tarailo-Graovac, M. Langeveld et al., "The role of the clinician in the multi-omics era: are you ready?," 2018. ncbi.nlm.nih.gov
39. N. Gholami, A. Haghparast, I. Alipourfard, and M. Nazari, "Prostate cancer in omics era," 2022. ncbi.nlm.nih.gov
40. I. da Silva, R. da Costa Vieira, C. Stella, E. Loturco et al., "Inborn-like errors of metabolism are determinants of breast cancer risk, clinical response and survival: a study of human biochemical individuality," 2018. ncbi.nlm.nih.gov

41. C. Silva, R. Perestrelo, P. Silva, H. Tomás et al., "Breast cancer metabolomics: from analytical platforms to multivariate data analysis. A review," 2019. [PDF]

42. E. Porcu, F. Gilardi, L. Darrous, L. Yengo et al., "Triangulating evidence from longitudinal and Mendelian randomization studies of metabolomic biomarkers for type 2 diabetes," 2021. ncbi.nlm.nih.gov

43. M. Zheng, C. Piermarocchi, and G. I. Mias, "Temporal response characterization across individual multiomics profiles of prediabetic and diabetic subjects," 2022. ncbi.nlm.nih.gov

44. M. Karaglani, K. Gourlia, I. Tsamardinos, and E. Chatzaki, "Accurate Blood-Based Diagnostic Biosignatures for Alzheimer's Disease via Automated Machine Learning," 2020. ncbi.nlm.nih.gov

45. N. J. Christodoulides, M. P. McRae, T. J. Abram, G. W. Simmons et al., "Innovative Programmable Bio-Nano-Chip Digitizes Biology Using Sensors That Learn Bridging Biomarker Discovery and Clinical Implementation," 2017. ncbi.nlm.nih.gov

46. C. T. Yu, B. N. Chao, R. Barajas, M. Haznadar et al., "An evaluation of the National Institutes of Health grants portfolio: identifying opportunities and challenges for multi-omics research that leverage metabolomics data," 2022. ncbi.nlm.nih.gov